MedTrace Logo

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

NCT03816228 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-03-13

No results posted yet for this study

Summary

To advance current knowledge on the vascular contributions to dementia

Conditions

  • Alzheimer Disease

Interventions

DRUG

F 18 T807 Flortaucipir

Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Sponsors & Collaborators

  • Tammie L. S. Benzinger, MD, PhD

    lead OTHER

Principal Investigators

  • Tammie Benzinger, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-10-11
Completion
2022-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03816228 on ClinicalTrials.gov